Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27942442 | 0.91 | SMN1; SMN2 (0.41) | SMN1; SMN2HTR4HTR3EHTR3BHTR3A | |
| SCHEMBL21003313 | 0.84 | KDM4E (0.44) | SMN1; SMN2HTR4ACHEKDM4E | |
| SCHEMBL14382462 | 0.83 | KDM4E (0.43) | SMN1; SMN2HTR4HTR3AACHEKDM4E | |
| SCHEMBL5316552 | 0.82 | HTR4 (0.47) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5316403 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2HTR4PRMT1KDM4EGLA | |
| SCHEMBL14382460 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2HTR4KDM4E | |
| SCHEMBL18019921 | 0.79 | HTR4 (0.34) | SMN1; SMN2HTR4HTR3EHTR3BHTR3A | |
| SCHEMBL7333211 | 0.78 | HTR4 (0.46) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9868328 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4E | |
| SCHEMBL6883903 | 0.76 | ACHE (0.36) | HTR4ACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | claimed |
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| WO-2007096352-A1 | 5-AMINO-6-BROMO-N-{ [1- (TETRAHYDR0-2H-PYRAN-4-YLMETHYL) -4-PIPERIDINYL] METHYL}-3, 4 -DIHYDRO-2H-CHROMENE-8-CARBOXAMIDE AS 5-HT4 RECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096352-A1 | 5-AMINO-6-BROMO-N-{ [1- (TETRAHYDR0-2H-PYRAN-4-YLMETHYL) -4-PIPERIDINYL] METHYL}-3, 4 -DIHYDRO-2H-CHROMENE-8-CARBOXAMIDE AS 5-HT4 RECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007068739-A1 | 4-AMINO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232657-A1 | NOVEL COMPOUNDS | HTR4, HTR5A, HTR6 | SMN1; SMN2 2023/4885HTR4 1/4885HTR3E 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.